Legend Biotech(US:LEGN) First Shanghai Securities·2025-11-26 11:44Investment Rating - The report maintains a "Buy" rating for Sands China (1928) with a target price of HKD 25.11, reflecting a potential upside of 27.9% from the current price [2][8]. Core Insights - Sands China's new promotional strategies are beginning to show results, with expectations for continued market share and EBITDA growth [5][7]. - The company reported a net revenue of USD 1.9 billion for Q3 2025, recovering to 90% of 2019 levels, with a year-on-year growth of 7.3% and a quarter-on-quarter growth of 6.1% [5]. - The adjusted EBITDA for Q3 2025 increased by 2.7% year-on-year and 6.2% quarter-on-quarter to USD 600 million, recovering to 80% of 2019 levels [5][7]. Summary by Sections Company Research - Sands China (1928) is rated "Buy" with a target price of HKD 25.11, reflecting a 12x EV/EBITDA for 2025 [2][8]. - The company’s market share in the gaming sector has rebounded to 25.4%, with a year-on-year increase of 0.5% and a quarter-on-quarter increase of 1.4% [5][7]. Financial Performance - Q3 2025 net profit increased by 1.5% year-on-year and 27.1% quarter-on-quarter to USD 270 million [5]. - The company holds approximately USD 1.13 billion in cash, with net debt reduced by USD 150 million to USD 5.79 billion [5][7]. Market Dynamics - The VIP segment saw a year-on-year decline of 16.3%, while the mass market segment grew by 12.1% year-on-year, indicating a shift in customer preferences [5][6]. - The company is benefiting from the full service of the Londoner project and new promotional strategies, which are expected to enhance market share and EBITDA further [7][8]. Other Key Points - The report highlights the importance of the new strategies and the expected growth in EBITDA to reach USD 2.7-2.8 billion in the short term [7]. - Sands China has repurchased USD 340 million worth of shares, increasing its ownership stake to 74.76% [7].